Amgen Inc (AMGN) 156.22 $AMGN
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome
PR Newswire - 51 mins ago
Amgen (NASDAQ: AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.
AMGN: 156.22 (+0.49)
Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 52 mins ago
Vertex Pharmaceuticals (VRTX) provided an update on its cystic fibrosis pipeline and issued preliminary financial guidance for 2015.
VRTX: 118.31 (-3.90), ALXN: 183.36 (-0.91), AMGN: 156.22 (+0.49), AMAG: 42.32 (-0.12)
Midday Glance: Biotechnology companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Global Venlafaxine Industry Report 2015-2020
M2 - Mon Jan 12, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzskl2/global) has announced the addition of the "Global Venlafaxine Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The venlafaxine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Venlafaxine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-one industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The venlafaxine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Venlafaxine Industry Overview - Global Venlafaxine Market Status Analysis - Major Regions Venlafaxine Market Status Analysis - Major Countries Venlafaxine Market Status and Analysis - Major Companies Venlafaxine Market Status and Analysis - Venlafaxine Industry Chain and Marketing Channels Analysis - Venlafaxine Industry Segment Market Analysis - Venlafaxine Industry Development Trend - Venlafaxine New Project Investment Feasibility Analysis - Global Venlafaxine Industry Research Conclusions Companies Mentioned - Abbott Laboratories - Amgen - Astellas - Astrazeneca - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly Inc - Genentech - Glaxosmithkline - Johnson & Johnson - Kanghong Pharmaceutical - Merck - Novartis - Otsuka - Pfize - Roche Group - Sanofi-Aventis - Shuaike - Takeda For more information visit http://www.researchandmarkets.com/research/bzskl2/global
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Early Glance: Biotechnology companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Hospira submits BLA for biosimilar to Amgen product
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:46AM CST
JNJ: 104.58 (-0.36), AMGN: 156.22 (+0.49), HSP: 61.55 (-0.09)
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar
PR Newswire - Mon Jan 12, 8:00AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Retacrit(TM), a proposed biosimilar to Amgen's EPOGEN® (epoetin alfa) and Janssen's PROCRIT ® (epoetin alfa).
AMGN: 156.22 (+0.49), HSP: 61.55 (-0.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Can You Guess the Most Common Reason People Visit the Doctor?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 6:14AM CST
Source: Flickr user Rusty Ferguson The Affordable Care Act, the health reform law better known as Obamacare, is quickly changing the medical care landscape. Gone are the days when insurers could deny coverage for preexisting conditions; now there...
MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86)
Final Glance: Biotechnology companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Regeneron rises on drug data
at Investor's Business Daily - Fri Jan 09, 5:42PM CST
A late-stage trial found alirocumab, co-developed by Regeneron (REGN) and Sanofi (SNY), was effective in fighting "bad" cholesterol, when injected every 4 weeks instead of 2 weeks. The report makes it easier for people with high cholesterol to take,...
AMGN: 156.22 (+0.49), SNY: 44.92 (+0.37), REGN: 413.33 (+2.29)
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 209.10 (-8.39), AMGN: 156.22 (+0.49), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Regeneron Jumps On Favorable Cholesterol Drug Report
at Investor's Business Daily - Fri Jan 09, 2:42PM CST
Regeneron (REGN) said an experimental drug it's developing with Sanofi (SNY) was found in a late-stage trial to be effective in fighting "bad" cholesterol, even when injected once every four weeks instead of two weeks. The report makes the drug,...
BMRN: 96.58 (+2.80), AMGN: 156.22 (+0.49), SNY: 44.92 (+0.37), REGN: 413.33 (+2.29)
3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jan 09, 1:30PM CST
Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several products.
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64)
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine
PR Newswire - Fri Jan 09, 7:00AM CST
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announces that it has acquired NextCODE Health, a leading genomic analysis and bioinformatics company with operations in the United States and Iceland, for $65 million in cash. WuXi plans to merge NextCODE Health and WuXi's Genome Center into a new company to be named WuXi NextCODE Genomics. The business will be headquartered in Shanghai, with operations in Cambridge, Massachusetts, and Reykjavik, Iceland. The leadership of WuXi NextCODE Genomics will include Dr. Ge Li as CEO, Edward Hu as CFO, Hannes Smarason as COO, Dr. Jeffrey Gulcher as CSO, Dr. Hongye Sun as CTO, and Dr. Hakon Gudbjartsson as VP Informatics.
AMGN: 156.22 (+0.49), WX: 37.22 (-0.54)
Ellen Feigal, MD, Former Senior Executive with CIRM and the National Cancer Institute (NCI), Joins NDA Partners as Premier Expert
PRWeb - Fri Jan 09, 2:03AM CST
Dr. Carl Peck, MD, Chairman of NDA Partners LLC announced today that Ellen G. Feigal, MD, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants whose expertise and professional stature enable them to bring extraordinary value to the company's clients. Premier Experts collaborate to design and implement critical solutions to help clients successfully develop their medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
AMGN: 156.22 (+0.49)
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome
PR Newswire - 51 mins ago
Amgen (NASDAQ: AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.
AMGN: 156.22 (+0.49)
Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 52 mins ago
Vertex Pharmaceuticals (VRTX) provided an update on its cystic fibrosis pipeline and issued preliminary financial guidance for 2015.
VRTX: 118.31 (-3.90), ALXN: 183.36 (-0.91), AMGN: 156.22 (+0.49), AMAG: 42.32 (-0.12)
Midday Glance: Biotechnology companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Global Venlafaxine Industry Report 2015-2020
M2 - Mon Jan 12, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzskl2/global) has announced the addition of the "Global Venlafaxine Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The venlafaxine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Venlafaxine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-one industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The venlafaxine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Venlafaxine Industry Overview - Global Venlafaxine Market Status Analysis - Major Regions Venlafaxine Market Status Analysis - Major Countries Venlafaxine Market Status and Analysis - Major Companies Venlafaxine Market Status and Analysis - Venlafaxine Industry Chain and Marketing Channels Analysis - Venlafaxine Industry Segment Market Analysis - Venlafaxine Industry Development Trend - Venlafaxine New Project Investment Feasibility Analysis - Global Venlafaxine Industry Research Conclusions Companies Mentioned - Abbott Laboratories - Amgen - Astellas - Astrazeneca - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly Inc - Genentech - Glaxosmithkline - Johnson & Johnson - Kanghong Pharmaceutical - Merck - Novartis - Otsuka - Pfize - Roche Group - Sanofi-Aventis - Shuaike - Takeda For more information visit http://www.researchandmarkets.com/research/bzskl2/global
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Early Glance: Biotechnology companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Hospira submits BLA for biosimilar to Amgen product
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:46AM CST
JNJ: 104.58 (-0.36), AMGN: 156.22 (+0.49), HSP: 61.55 (-0.09)
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar
PR Newswire - Mon Jan 12, 8:00AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Retacrit(TM), a proposed biosimilar to Amgen's EPOGEN® (epoetin alfa) and Janssen's PROCRIT ® (epoetin alfa).
AMGN: 156.22 (+0.49), HSP: 61.55 (-0.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Can You Guess the Most Common Reason People Visit the Doctor?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 6:14AM CST
Source: Flickr user Rusty Ferguson The Affordable Care Act, the health reform law better known as Obamacare, is quickly changing the medical care landscape. Gone are the days when insurers could deny coverage for preexisting conditions; now there...
MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86)
Final Glance: Biotechnology companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Regeneron rises on drug data
at Investor's Business Daily - Fri Jan 09, 5:42PM CST
A late-stage trial found alirocumab, co-developed by Regeneron (REGN) and Sanofi (SNY), was effective in fighting "bad" cholesterol, when injected every 4 weeks instead of 2 weeks. The report makes it easier for people with high cholesterol to take,...
AMGN: 156.22 (+0.49), SNY: 44.92 (+0.37), REGN: 413.33 (+2.29)
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 209.10 (-8.39), AMGN: 156.22 (+0.49), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Regeneron Jumps On Favorable Cholesterol Drug Report
at Investor's Business Daily - Fri Jan 09, 2:42PM CST
Regeneron (REGN) said an experimental drug it's developing with Sanofi (SNY) was found in a late-stage trial to be effective in fighting "bad" cholesterol, even when injected once every four weeks instead of two weeks. The report makes the drug,...
BMRN: 96.58 (+2.80), AMGN: 156.22 (+0.49), SNY: 44.92 (+0.37), REGN: 413.33 (+2.29)
3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jan 09, 1:30PM CST
Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several products.
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64)
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine
PR Newswire - Fri Jan 09, 7:00AM CST
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announces that it has acquired NextCODE Health, a leading genomic analysis and bioinformatics company with operations in the United States and Iceland, for $65 million in cash. WuXi plans to merge NextCODE Health and WuXi's Genome Center into a new company to be named WuXi NextCODE Genomics. The business will be headquartered in Shanghai, with operations in Cambridge, Massachusetts, and Reykjavik, Iceland. The leadership of WuXi NextCODE Genomics will include Dr. Ge Li as CEO, Edward Hu as CFO, Hannes Smarason as COO, Dr. Jeffrey Gulcher as CSO, Dr. Hongye Sun as CTO, and Dr. Hakon Gudbjartsson as VP Informatics.
AMGN: 156.22 (+0.49), WX: 37.22 (-0.54)
Ellen Feigal, MD, Former Senior Executive with CIRM and the National Cancer Institute (NCI), Joins NDA Partners as Premier Expert
PRWeb - Fri Jan 09, 2:03AM CST
Dr. Carl Peck, MD, Chairman of NDA Partners LLC announced today that Ellen G. Feigal, MD, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants whose expertise and professional stature enable them to bring extraordinary value to the company's clients. Premier Experts collaborate to design and implement critical solutions to help clients successfully develop their medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
AMGN: 156.22 (+0.49)
